Skip to main content
Top
Published in: International Urology and Nephrology 8/2017

Open Access 01-08-2017 | Nephrology – Original Paper

Unexpected and striking effect of heparin-free dialysis on cytokine release

Authors: Alicja Rydzewska-Rosolowska, Joanna Gozdzikiewicz-Lapinska, Jacek Borawski, Ewa Koc-Zorawska, Michal Mysliwiec, Beata Naumnik

Published in: International Urology and Nephrology | Issue 8/2017

Login to get access

Abstract

Heparin (both unfractionated and low molecular weight) is not only a potent anticoagulant but also has many pleiotropic effects, some of which are mediated by cytokine release. We compared the effect of hemodialysis (HD) with enoxaparin as an anticoagulant and without systemic anticoagulation (heparin-grafted membrane—Evodial) on the release of monocyte chemoattractant protein 1 (MCP-1), endostatin (ES) and activin A (Act-A). Nineteen stable HD patients were dialyzed with or without heparin, and plasma levels of MCP-1, ES and Act-A were measured after such a dialysis. During HD with Evodial, the intradialytic levels of all three cytokines were 2–3 folds lower. The between-anticoagulant differences were significant over time for all three cytokines: MCP-1 (P < 0.001), ES (P < 0.001) and Act-A (P < 0.001). This striking effect of heparin-free dialysis with Evodial membrane may be beneficial not only because it reduces the possibility of bleeding complications but also because it might reduce proinflammatory cytokine concentration and therefore contribute to the improvement in endothelial function. Further studies are needed to determine whether it has a positive effect on morbidity and mortality of maintenance HD patients.
Literature
1.
go back to reference Fareed J, Hoppensteadt DA (2000) Heparins in the new millennium: will unfractionated heparin survive? Epilogue. Semin Thromb Hemost 26(Suppl 1):87–88PubMed Fareed J, Hoppensteadt DA (2000) Heparins in the new millennium: will unfractionated heparin survive? Epilogue. Semin Thromb Hemost 26(Suppl 1):87–88PubMed
2.
go back to reference Fareed J, Hoppensteadt DA, Bick RL (2000) An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 26(Suppl 1):5–21CrossRefPubMed Fareed J, Hoppensteadt DA, Bick RL (2000) An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 26(Suppl 1):5–21CrossRefPubMed
3.
go back to reference Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, Moroni E, Liekens S, Rusnati M (2003) Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 9(7):553–566CrossRefPubMed Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, Moroni E, Liekens S, Rusnati M (2003) Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 9(7):553–566CrossRefPubMed
5.
go back to reference Rydzewska-Rosolowska A, Borawski J, Mysliwiec M (2009) Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins. Ren Fail 31(9):791–797. doi:10.3109/08860220903180608 CrossRefPubMed Rydzewska-Rosolowska A, Borawski J, Mysliwiec M (2009) Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins. Ren Fail 31(9):791–797. doi:10.​3109/​0886022090318060​8 CrossRefPubMed
9.
go back to reference Akahoshi T, Kobayashi N, Hosaka S, Sekiyama N, Wada C, Kondo H (1995) In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant 10(12):2244–2249CrossRefPubMed Akahoshi T, Kobayashi N, Hosaka S, Sekiyama N, Wada C, Kondo H (1995) In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant 10(12):2244–2249CrossRefPubMed
10.
go back to reference Jacobson SH, Egberg N, Hylander B, Lundahl J (2002) Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 22(1):42–47. doi:10.1159/000046673 CrossRefPubMed Jacobson SH, Egberg N, Hylander B, Lundahl J (2002) Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 22(1):42–47. doi:10.​1159/​000046673 CrossRefPubMed
13.
go back to reference Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404–407. doi:10.1038/37126 CrossRefPubMed Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404–407. doi:10.​1038/​37126 CrossRefPubMed
14.
go back to reference Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H (2005) Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54(10):2891–2903. doi:10.2337/diabetes.54.10.2891 CrossRefPubMed Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H (2005) Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54(10):2891–2903. doi:10.​2337/​diabetes.​54.​10.​2891 CrossRefPubMed
15.
16.
go back to reference Feldman AL, Alexander HR Jr, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK (2002) Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95(8):1637–1643. doi:10.1002/cncr.10845 CrossRefPubMed Feldman AL, Alexander HR Jr, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK (2002) Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95(8):1637–1643. doi:10.​1002/​cncr.​10845 CrossRefPubMed
18.
go back to reference Morena M, Jaussent I, Chalabi L, Bargnoux AS, Dupuy AM, Badiou S, Rakic C, Thomas M, Canaud B, Cristol JP, Michel F (2010) Biocompatibility of heparin-grafted hemodialysis membranes: impact on monocyte chemoattractant protein-1 circulating level and oxidative status. Hemodial Int 14(4):403–410. doi:10.1111/j.1542-4758.2010.00494.x CrossRefPubMed Morena M, Jaussent I, Chalabi L, Bargnoux AS, Dupuy AM, Badiou S, Rakic C, Thomas M, Canaud B, Cristol JP, Michel F (2010) Biocompatibility of heparin-grafted hemodialysis membranes: impact on monocyte chemoattractant protein-1 circulating level and oxidative status. Hemodial Int 14(4):403–410. doi:10.​1111/​j.​1542-4758.​2010.​00494.​x CrossRefPubMed
20.
go back to reference Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, Memmos D (2002) Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 17(3):435–441CrossRefPubMed Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, Memmos D (2002) Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 17(3):435–441CrossRefPubMed
21.
go back to reference Mandayam S, Shahinian VB (2008) Are chronic dialysis patients at increased risk for cancer? J Nephrol 21(2):166–174PubMed Mandayam S, Shahinian VB (2008) Are chronic dialysis patients at increased risk for cancer? J Nephrol 21(2):166–174PubMed
22.
go back to reference Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H (1997) A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem 272(21):13835–13842CrossRefPubMed Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H (1997) A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem 272(21):13835–13842CrossRefPubMed
25.
go back to reference Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, Phillips DJ (2007) Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 104(41):16239–16244. doi:10.1073/pnas.0705971104 CrossRefPubMedPubMedCentral Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, Phillips DJ (2007) Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 104(41):16239–16244. doi:10.​1073/​pnas.​0705971104 CrossRefPubMedPubMedCentral
Metadata
Title
Unexpected and striking effect of heparin-free dialysis on cytokine release
Authors
Alicja Rydzewska-Rosolowska
Joanna Gozdzikiewicz-Lapinska
Jacek Borawski
Ewa Koc-Zorawska
Michal Mysliwiec
Beata Naumnik
Publication date
01-08-2017
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2017
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1589-8

Other articles of this Issue 8/2017

International Urology and Nephrology 8/2017 Go to the issue